Clinical Trials

MGC Pharmaceuticals Ltd currently has three vital clinical trials in progress and a robust preclinical pipeline to support future development.

Supporting multiple products enroute to central market authorization

While enhancing the available research and evidence to support wider scale implementation of both plant-based and cannabinoid focused treatments.

MGC’s robust preclinical pipeline ensures future growth for the company as well as deepening the areas of engagement where we believe plant based medicines will have the most significant impact.

Leading the global shift towards plant-based, naturally harmonious medicines, improving lives and public health.

MGC Pharma’s phase III clinical trial has been designed to evaluate the efficacy and safety of CimetrA™ as a treatment for hospitalised patients diagnosed with COVID-19, and to provide additional data for claims on the product as an Investigational Medicinal Product (IMP). The trial will enrol a total of 252 patients and will be conducted over a 28-day period.

The Israeli Ministry of Health approval has now been received and the trial will shortly be initiated at the two clinical sites, Rambam Health Care Campus and Nazareth Hospital EMMS in Israel. This follows receipt of ethics committee approval in March 2021 (see ASX announcement 23 March 2021).

Interim results of the trial were expected to be released in August 2021. However, the Company is currently enrolling patients into a Phase IIb Dosing Study for CimetrA, which aims to determine the optimum dosage of CimetrA to treat
patients suffering from COVID-19, with these results to inform the dosage used in the Phase III trial. 

Once enrolments into the Phase III trial recommence, the company intends to expand this trial to strategic global jurisdictions.




ArtemiC was tested for safety and efficacy in a double-blind, placebo-controlled clinical trial involving 50 patients diagnosed with COVID-19.

In a Phase II clinical trials, ArtemiC statistically improved the recovery of patients infected with COVID-19. All patients had a confirmed COVID-19 infection, were hospitalized in a stable, moderate condition and were between the ages of 40 and 75. By the end of the two-week trial, 100% of the patients in the treatment group had shown improvement.

Within 15 days of follow-up, all had fully recovered. No patients in the treatment group required additional medical intervention and no adverse reactions to the treatment were recorded.

Those who were treated with ArtemiC showed:

  • 100% met all FDA primary and secondary end points
  • Improved clinical recovery
  • Improvement of symptoms and pain
  • Faster overall recovery time
  • No requirement for additional medical assistance (ICU, ventilation

CogniCann® – Phase II clinical trial
The Phase II clinical trial at the University of Notre Dame in Perth, Western Australia has been designed to evaluate the potential behavioral benefits of CogniCann® on patients with dementia and Alzheimer’s disease. The trial will enrol 50 patients and is expected to last until Q2 2022.

Initial recruitment commenced in January 2020 but was temporarily suspended due to the COVID-19 restrictions in WA. Recruit has recommenced and 21 patients have been enrolled in the trial over the last three months. Interim results are expected to be released in Q2 2022.

All three trials are well funded, following the successful £6.5 million IPO fundraising and listing on the London Stock Exchange in February 2021, and the Company will make further updates on them in due course.

CannEpil® (MGCND00EP1) – Phase IIb randomised, double blind, placebo controlled clinical study.

The phase IIb clinical trial will take place at the Schindler Hospital in Israel and will focus on the safety and efficacy of CannEpil® as an add-on treatment in children and adolescents with treatment resistant epilepsy, also known as refractory epilepsy. A total of more than 100 patients will be recruited into the trial.

The study drug import process has commenced following Israeli Ministry of Health approval. The trial will be initiated in July and the first patient is expected to be enrolled in June 2022. Interim results of the trial are expected in Q4 2022.

MGC has already initiated a Driving Safety study of CannEpil® in Australia following the reopening of universities after the COVID-19 lockdowns. This trial involves healthy volunteers and aims to demonstrate the safety of CannEpil® in order to provide supportive data to the regulatory authorities.

Rob Clements

Chief Commercial Officer

After starting his career with an initial spell in the City of London Rob joined the pharmaceutical industry in 1991. Over the following decade he progressed rapidly through field roles to Marketing Management. He then established his own consultancy specialising in relationship marketing and product launch for healthcare companies.

He subsequently worked in business development roles identifying potential product acquisitions – both prescription and OTC – the development and launch of medical devices and general strategic functions. His roles included improving business performance and company morale, and oversight of companies’ core marketing of ethical brands.

From 2011 Rob headed a pan-national team for Forest Laboratories delivering new ethical products to markets alongside management of the existing portfolio. As Director both of Marketing and Commercial operations he was also directly responsible for budgeting, planning and data provision, whilst remaining closely involved with the assessment of BD opportunities.

An expert in specialist disease marketing and business development Rob has also worked extensively on a number of proposed private equity asset buyouts in addition to previous consultancy work.

From 2019 he worked with Healthcare at Home (now Sciensus Rare) to help establish an international rare medicines division. As Vice President of Business Development his role included ongoing development and refinement of the service offering and building new business opportunities; from strategic partnerships and potential MA acquisitions through to establishing Sciensus Rare’s global footprint.